Vickerman Investment Advisors Inc. Has $3.95 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Vickerman Investment Advisors Inc. grew its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 10.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,687 shares of the medical research company's stock after purchasing an additional 1,222 shares during the period. Amgen makes up approximately 0.9% of Vickerman Investment Advisors Inc.'s holdings, making the stock its 27th largest holding. Vickerman Investment Advisors Inc.'s holdings in Amgen were worth $3,953,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of AMGN. Pinney & Scofield Inc. acquired a new position in shares of Amgen during the fourth quarter worth approximately $26,000. First Pacific Financial boosted its position in Amgen by 304.5% in the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company's stock valued at $28,000 after buying an additional 67 shares during the last quarter. Ritter Daniher Financial Advisory LLC DE increased its stake in shares of Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after buying an additional 51 shares during the period. Atala Financial Inc bought a new stake in shares of Amgen during the fourth quarter worth $34,000. Finally, Heck Capital Advisors LLC acquired a new position in shares of Amgen during the fourth quarter valued at $36,000. Institutional investors own 76.50% of the company's stock.

Amgen Stock Performance

Shares of AMGN traded down $4.42 during mid-day trading on Monday, hitting $293.82. 702,372 shares of the company's stock were exchanged, compared to its average volume of 2,840,642. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 8.70. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The stock's 50-day simple moving average is $282.47 and its 200-day simple moving average is $287.17. The firm has a market cap of $157.99 billion, a price-to-earnings ratio of 26.81, a price-to-earnings-growth ratio of 2.70 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. The firm had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The company's revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the company posted $3.96 EPS. On average, equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. William Blair reissued an "outperform" rating on shares of Amgen in a report on Tuesday, June 24th. Guggenheim started coverage on shares of Amgen in a report on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 price objective on the stock. Erste Group Bank cut shares of Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Wall Street Zen raised shares of Amgen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 18th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and set a $305.00 price objective on shares of Amgen in a research note on Tuesday, June 24th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $307.82.

Insider Buying and Selling

In other news, SVP Rachna Khosla sold 1,500 shares of the business's stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the transaction, the senior vice president owned 8,162 shares of the company's stock, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.69% of the stock is currently owned by corporate insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.